Retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases, stratified by extrahepatic metastases status.

ABSTRACT:

Background

Current decision-making for the treatment of breast cancer liver metastases (BCLM) using ablation lacks strong evidence, especially for patients combined with extrahepatic metastases.

Purpose

To assess whether ablation plus systemic therapy (AS) improves survival outcomes in patients with BCLM compared to systemic therapy alone.

Materials and methods

This retrospective study analyzed patients with BCLM who received either AS or systemic therapy alone. Propensity score matching (PSM) and survival analysis were performed, taking into account factors like the characteristics of primary breast cancer, liver metastases and systemic therapies received.

Results

The study included 1021 female patients, with a median follow-up of 39.6 months. Of these patient

SUBMITTER: Zou X 

PROVIDER: S-EPMC11782866 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature